Clinical trial
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
NCT00044291 is registered in ClinicalTrials.gov with Intarcia Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
- Lead sponsor
- Intarcia Therapeutics
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2002
- Completion date
- January 31, 2006
- Enrollment
- 865 (actual)
- Sites
- 63
Conditions
As the registry lists them; a condition with its own page is linked.